JP2003519096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003519096A5 JP2003519096A5 JP2001516562A JP2001516562A JP2003519096A5 JP 2003519096 A5 JP2003519096 A5 JP 2003519096A5 JP 2001516562 A JP2001516562 A JP 2001516562A JP 2001516562 A JP2001516562 A JP 2001516562A JP 2003519096 A5 JP2003519096 A5 JP 2003519096A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- binding agent
- mammal
- administered
- therapeutic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011230 binding agent Substances 0.000 description 35
- 206010028980 Neoplasm Diseases 0.000 description 34
- 238000000034 method Methods 0.000 description 26
- 241000124008 Mammalia Species 0.000 description 24
- 102100034256 Mucin-1 Human genes 0.000 description 17
- 108010008707 Mucin-1 Proteins 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 16
- 230000037396 body weight Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- VANSZAOQCMTTPB-SETSBSEESA-N hypocrellin Chemical compound C1[C@@](C)(O)[C@@H](C(C)=O)C2=C(OC)C(O)=C3C(=O)C=C(OC)C4=C3C2=C2C3=C4C(OC)=CC(=O)C3=C(O)C(OC)=C21 VANSZAOQCMTTPB-SETSBSEESA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- KGHNSNSWRMJVND-UHFFFAOYSA-N Hypocrellin Natural products COC1=CC(=O)C2=C3C4C(C(C(=O)C)C(C)(O)Cc5c(OC)c(O)c6C(=O)C=C(OC)C(=C13)c6c45)C(=C2O)OC KGHNSNSWRMJVND-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 108010017838 cyclo-(lysyl-prolyl-glycyl-prolyl-glycyl-glutamyl-prolyl-glycyl-prolyl-glycyl)cyclo(1epsilon-6gamma)glycyl-glycine Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BQJKVFXDDMQLBE-UHFFFAOYSA-N shiraiachrome A Natural products COC1=C2C3=C(OC)C=C(O)C4=C3C3=C5C(CC(C)(O)C(C(C)=O)C3=C(OC)C4=O)=C(OC)C(=O)C(C(O)=C1)=C25 BQJKVFXDDMQLBE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14949299P | 1999-08-18 | 1999-08-18 | |
| US60/149,492 | 1999-08-18 | ||
| US16471499P | 1999-11-11 | 1999-11-11 | |
| US60/164,714 | 1999-11-11 | ||
| PCT/US2000/022890 WO2001012217A1 (en) | 1999-08-18 | 2000-08-18 | Therapeutic antibody against muc-1 antigen and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011193430A Division JP2012046518A (ja) | 1999-08-18 | 2011-09-06 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003519096A JP2003519096A (ja) | 2003-06-17 |
| JP2003519096A5 true JP2003519096A5 (cg-RX-API-DMAC7.html) | 2007-09-27 |
Family
ID=26846783
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001516562A Withdrawn JP2003519096A (ja) | 1999-08-18 | 2000-08-18 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
| JP2011193430A Pending JP2012046518A (ja) | 1999-08-18 | 2011-09-06 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011193430A Pending JP2012046518A (ja) | 1999-08-18 | 2011-09-06 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1204423B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2003519096A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE290879T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU782569B2 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60018761T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2239032T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001012217A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
| WO2002058450A2 (en) | 2000-12-22 | 2002-08-01 | Dana-Faber Cancer Institute, Inc. | Regulation of cell growth by muc1 |
| US6627664B2 (en) * | 2001-01-30 | 2003-09-30 | Altachem Pharma Ltd. | Perylenequinones for use as sonosensitizers |
| US20040110846A1 (en) * | 2001-01-30 | 2004-06-10 | Beatrice Leveugle | Perylenequinones for use with immunotherapy agents |
| ES2424131T3 (es) | 2001-03-27 | 2013-09-27 | Oncothyreon Inc. | Vacuna para modular respuestas inmunitarias entre T1 y T2 |
| AU2002358246B2 (en) * | 2001-10-26 | 2008-02-28 | Oncoquest Pharmaceuticals Inc. | Combination therapy for treating disease |
| CN100356984C (zh) * | 2002-01-24 | 2007-12-26 | 巴内斯－朱威胥医院 | 整联蛋白靶向的影像剂 |
| DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| WO2005042573A1 (en) | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
| TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
| EP1848804B1 (en) * | 2005-01-28 | 2011-10-05 | Ramot at Tel Aviv University, Ltd. | Anti-muc1 alpha beta antibodies |
| PT2366400E (pt) | 2005-06-28 | 2016-02-02 | Oncothyreon Inc | Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1) |
| US8506931B2 (en) | 2005-08-10 | 2013-08-13 | Quest Pharmatech Inc. | Perylenequinone derivatives and uses thereof |
| US8454991B2 (en) | 2006-07-24 | 2013-06-04 | Quest Pharmatech Inc. | Method and device for photodynamic therapy |
| WO2008028686A2 (en) | 2006-09-10 | 2008-03-13 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| PL1920781T3 (pl) | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
| WO2008097844A2 (en) | 2007-02-02 | 2008-08-14 | Dana -Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins |
| WO2008097840A2 (en) | 2007-02-02 | 2008-08-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of muc1 by hsf1 and stat3 |
| CA2741798A1 (en) | 2008-10-28 | 2010-05-06 | Shionogi & Co., Ltd. | Anti-muc1 antibody |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| WO2011135869A1 (ja) | 2010-04-28 | 2011-11-03 | 塩野義製薬株式会社 | 新規なｍｕｃ１抗体 |
| JP2014518841A (ja) | 2011-02-24 | 2014-08-07 | オンコシレオン インク． | アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン |
| EP2748302B1 (en) | 2011-08-22 | 2018-08-15 | Glycotope GmbH | Microorganisms carrying a tumor antigen |
| JP2017009287A (ja) * | 2013-11-11 | 2017-01-12 | 東ソー株式会社 | 前立腺癌と前立腺肥大症との識別方法 |
| JP6476170B2 (ja) | 2014-04-28 | 2019-03-06 | 医化学創薬株式会社 | 抗ｍｕｃ１抗体又はその抗原結合性断片及びその用途 |
| US20190343953A1 (en) * | 2017-01-27 | 2019-11-14 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| EP3794042B1 (en) | 2018-05-18 | 2024-03-27 | Daiichi Sankyo Co., Ltd. | Anti-muc1- exatecan antibody-drug conjugate |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993020841A1 (en) * | 1992-04-13 | 1993-10-28 | Dana-Farber Cancer Institute, Inc. | Antibodies specific for carcinoma-associated antigens |
| FI950062A7 (fi) * | 1992-07-06 | 1995-01-05 | Biomira Inc | Proteiinien foroaktivaatio konjugaatiotarkoituksia varten |
| WO1994011508A2 (en) * | 1992-11-13 | 1994-05-26 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
| DE19534630A1 (de) * | 1995-09-18 | 1997-03-20 | Max Delbrueck Centrum | Monoklonale Antikörper gegen epitheliales Muzin (MUC1) |
| WO1997042973A1 (en) * | 1996-05-15 | 1997-11-20 | Altarex, Corp. | Method and composition for reconforming multi-epitopic antigens to initiate an immune response |
| AU6017198A (en) * | 1997-01-10 | 1998-08-25 | Altarex Corp. | Substituted perylenequinones for use in photodynamic therapy |
| EP1056472A2 (en) * | 1998-02-13 | 2000-12-06 | BASTERT, Gunter, Prof.Dr.med.Dr.h.c. | Specific antibodies against mammary tumor-associated mucin, method for production and use |
-
2000
- 2000-08-18 JP JP2001516562A patent/JP2003519096A/ja not_active Withdrawn
- 2000-08-18 AT AT00957617T patent/ATE290879T1/de active IP Right Revival
- 2000-08-18 WO PCT/US2000/022890 patent/WO2001012217A1/en not_active Ceased
- 2000-08-18 EP EP00957617A patent/EP1204423B1/en not_active Expired - Lifetime
- 2000-08-18 AU AU69211/00A patent/AU782569B2/en not_active Ceased
- 2000-08-18 DE DE60018761T patent/DE60018761T2/de not_active Expired - Lifetime
- 2000-08-18 ES ES00957617T patent/ES2239032T3/es not_active Expired - Lifetime
-
2011
- 2011-09-06 JP JP2011193430A patent/JP2012046518A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mew et al. | Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. | |
| CN106456794B (zh) | 接头药物与抗体的位点特异性缀合以及所得adc | |
| JP2023162436A (ja) | 抗ｆｏｌｒ１免疫複合体投与計画 | |
| Blumenthal et al. | Comparison of therapeutic efficacy and host toxicity of two different 131I‐labelled antibodies and their fragments in the GW‐39 colonic cancer xenograft model | |
| US20090192071A1 (en) | Use of photodynamic therapy to enhance treatment with immuno-modulating agents | |
| WO2002100326A3 (en) | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies | |
| JP2005517674A (ja) | 腫瘍の処置に有用な新規免疫コンジュゲート | |
| MXPA02010059A (es) | Metodo para administrar un anticuerpo. | |
| JP2003517461A5 (cg-RX-API-DMAC7.html) | ||
| JP2024530368A5 (cg-RX-API-DMAC7.html) | ||
| JP2012046518A (ja) | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 | |
| PT910407E (pt) | Metodo e composicao para modificar a conformacao de antigenios multi-epitopicos de modo a iniciar uma resposta imunitaria | |
| Remsen et al. | Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model | |
| US6022541A (en) | Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel | |
| Punyakoti et al. | Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer's disease | |
| JPS63238023A (ja) | 抗腫瘍イムノトキシン及び腫瘍壊死因子を含んで成る医薬 | |
| JP2025535447A5 (cg-RX-API-DMAC7.html) | ||
| JPH10508868A (ja) | ＴＰ−３／ｐ８０を標的とする癌の生物療法 | |
| US5151266A (en) | Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies | |
| Lee et al. | Antibodies as specific carriers for chemotherapeutic agents | |
| Schulz et al. | Immunotherapy of pancreatic cancer with monoclonal antibody BW 494 | |
| EP0213881B1 (en) | The use of amphipathic molecules for radioimaging and therapy with conjugates of monoclonal or polyclonal antibodies | |
| Büchler et al. | Studies of pancreatic cancer utilizing monoclonal antibodies | |
| WO1994023753A1 (en) | Cancer therapy, using antibody conjugates, in combination with a vasoactive agent | |
| JP3676915B2 (ja) | 雑種細胞の注射による腫瘍免疫の誘導 |